Immuno Oncology Therapy Articles & Analysis
26 news found
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be ...
ByBayer AG
As part of the management team changes, Stefan Braam, the founder of Ncardia and Cellistic, will move into the role of President and Chief Technical Officer where he will oversee the group’s technical matters, including investments in unique turn-key immuno-oncology iPSC-based cell therapy platforms. “We are thrilled with the ...
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in ...
She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General Director of the Immunology Business Unit at Ardigen, where she focuses on developing AI platforms to solve therapy ...
ByArdigen
“Similar to the Ardigen team, I have dedicated my career to immuno-oncology with special interest in cellular therapy. I strongly believe that this modality has great curative potential and will give hope to terminally-ill patients. ...
ByArdigen
Ulrike Köhl, Professor of Immuno-Oncology, University of Leipzig, director of the Fraunhofer Institute for Cell Therapy and Immunology, Leipzig as well as director of the Institute of Cellular Therapeutics, Hannover Medical School, Germany, a leading expert in the development and manufacturing of cell and gene therapies in ...
Partnering with Umoja is an important step forward in immuno-oncology. Besides scale-up and cell quality, the in vivo persistence of allogeneic therapies remains a critical challenge in the industry. We believe Umoja’s platform will allow for safer and more efficient allogeneic cell therapies in ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. ...
Julie has served as President and Chief Executive Officer at several biotechnology companies, including QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. ...
The therapeutic candidate is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers active compounds directly to tumor-resident immune cells. ...
About Actym Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer ...
Actym Therapeutics, a privately-held biotechnology company focused on the discovery and development of novel immuno-oncology therapies to treat cancer, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent that protects the company's therapeutic technology platform. ...
GI Innovation, Inc., (CEO, Jun Ho Hong) announced that GI Innovation signed a clinical supply collaboration agreement with global biopharmaceutical company AstraZeneca for development of GI-101 and Imfinzi® combination therapy. Under this agreement, GI Innovation and AstraZeneca will conduct a clinical trial assessing triplet combination regimen of GI-101, Imfinzi® (durvalumab) and ...
Bristol Myers Squibb’s global clinical development and commercialization capabilities in oncology make them the ideal partner for the further development of IMA401.” “We are pleased to expand our collaboration with Immatics to now include IMA401,” said Teri Foy, Senior Vice President, Research and Early Development, ...
ACTM-838 is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. ...
"Actym's novel S. Typhimurium-Attenuated Cancer Therapy (STACT) therapies have the unique ability to bring immunogenic payloads to the tumor microenvironment to promote potent and durable anti-tumor responses to tackle difficult to treat cancers. ...
Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the growth of its pipeline of predictive response signatures for oncology therapeutics. New investors include IAG Capital Partners and Alexandria Venture Investments, along with existing investors Labcorp and Hatteras Venture Partners. ...
Our goal is to provide the best possible information for evidence-based therapy decisions at all times,” explains Dr. Matthias Kopf, Head of Product Management at Molecular Health. MH Guide is a browser-based software that is used in therapy planning for cancer patients. The software enables the automatic analysis of molecular data obtained using Next ...
Our expansion into functional genomics will help our partners tackle their most pressing questions in therapy development and will ultimately improve the lives of many patients.” By partnering with pharmaceutical, biotech, and academic leaders and building its own pipeline, Immunai is poised to answer the most pressing questions in ...
ByImmunai
Ramy has also spent more than a decade working at major pharma companies, advancing the early stages of immuno-oncology therapies. He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD. ...
Bybit.bio